Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
100%
Overall Survival
54%
Abiraterone
45%
Docetaxel
44%
Phase II Trial
43%
Advanced Prostate Cancer
41%
Abiraterone Acetate
41%
Consensus Conference
41%
Sunitinib
34%
Patient Management
27%
Placebo
27%
MicroRNA
27%
Neutrophil-to-lymphocyte Ratio
27%
Prostate-specific Antigen
26%
T Cells
25%
Muscle-invasive Bladder Cancer
24%
Melanoma
21%
Bladder Cancer
21%
Advanced Renal Cell Carcinoma
20%
Pembrolizumab
20%
Immune Checkpoint Inhibitors
20%
Autoimmune T Cells
19%
Neoadjuvant Chemotherapy
18%
Prostate Cancer
17%
Chemotherapy
17%
Prostate
17%
Progression-free Survival
16%
Prostate Radiotherapy
16%
Cancer Patients
16%
Prostate Cancer Patients
15%
Metastatic Melanoma
15%
Hazard Ratio
15%
PSA Response
14%
Urothelial Carcinoma
14%
Programmed Death-ligand 1 (PD-L1)
14%
Malignant Melanoma
14%
Objective Response Rate
14%
Tumor
13%
Radionuclide Therapy
13%
Scattering Factor
13%
Locally Advanced or Metastatic Urothelial Carcinoma
13%
Ramucirumab
13%
Hepatocyte Growth Factor
13%
Mitochondrial Carrier
13%
Mimp
13%
COVID-19 Pandemic
13%
Randomized Double-blind
13%
Platinum Therapy
13%
Ketoconazole
13%
Nivolumab Plus Ipilimumab
13%
Medicine and Dentistry
Prostate Cancer
75%
Castration Resistant Prostate Cancer
69%
Overall Survival
59%
Lymphocyte
40%
Neutrophil
37%
Transitional Cell Carcinoma
35%
Sunitinib
34%
Abiraterone Acetate
34%
Diseases
33%
Abiraterone
32%
Clear Cell Renal Cell Carcinoma
27%
Muscle Invasive Bladder Cancer
25%
Malignant Neoplasm
22%
Progression Free Survival
22%
Recurrent Disease
22%
Nivolumab
20%
Neoadjuvant Chemotherapy
20%
Melanoma
20%
Pembrolizumab
20%
Placebo
20%
Adverse Event
18%
Biological Marker
18%
Docetaxel
17%
Clinical Trial
17%
Immune Checkpoint Inhibitor
16%
Ipilimumab
15%
Prostate Specific Antigen
15%
Prostate Specific Membrane Antigen
14%
COVID-19
14%
Hypofractionated Radiotherapy
13%
Positron Emission Tomography-Computed Tomography
13%
Ketoconazole
13%
Epacadostat
13%
Neoplasm
12%
Radiation Therapy
12%
Immunotherapy
11%
Hazard Ratio
11%
Antigen Response
10%
Gallium 68
9%
Messenger RNA
9%
Conformal Radiotherapy
9%
Non Small Cell Lung Cancer
9%
Disease Free Survival
9%
Androgen
9%
Lactate Dehydrogenase
9%
Kidney Metastasis
8%
Biochemical Recurrence
8%
Oncology
8%
Proportional Hazards Model
8%
Comorbidity
8%